Work Here?
Arrowhead Pharmaceuticals
Work Here?
Develops RNAi-based therapies for diseases
Arrowhead Pharmaceuticals
Work Here?
Develops RNAi-based therapies for diseases
About Arrowhead Pharmaceuticals
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Pasadena, California
Founded
2004
Overview
Arrowhead Pharmaceuticals develops medicines that target and silence genes responsible for severe diseases using RNA interference (RNAi). This approach allows the company to effectively reduce the expression of specific genes, potentially halting or reversing the progression of conditions like cystic fibrosis and hepatitis B. Arrowhead stands out from competitors by focusing on RNAi-based therapies to address unmet medical needs. The company's goal is to provide new treatment options for patients suffering from genetic disorders.
Simplify's Take
What believers are saying
- Arrowhead's collaboration with Sarepta includes a $500M upfront payment for RNA drug development.
- Positive Phase 2 data for plozasiran boosts Arrowhead's credibility in treating hypertriglyceridemia.
- Strategic financing with Sixth Street provides capital to advance Arrowhead's research pipeline.
What critics are saying
- Increased competition from companies like Alnylam may impact Arrowhead's market share.
- Potential regulatory scrutiny could delay Arrowhead's clinical trials for RNAi therapies.
- Reliance on strategic financing may lead to increased debt obligations for Arrowhead.
What makes Arrowhead Pharmaceuticals unique
- Arrowhead uses RNAi to target and silence disease-causing genes effectively.
- The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
- Arrowhead's strategic partnerships enhance its capabilities in developing innovative RNAi therapies.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1372.2M
Above
Industry Average
Funded Over
2 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Company News
Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.
Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.
New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides
Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.
Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.
Arrowhead Pharmaceuticals is Hiring for 48 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Arrowhead Pharmaceuticals
About Arrowhead Pharmaceuticals
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Pasadena, California
Founded
2004
Arrowhead Pharmaceuticals is Hiring for 48 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Arrowhead Pharmaceuticals